Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis

References

• Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360(9347):1747–1748.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol. 2004;94(7):901–906.
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–387.
   Google Scholar
• Gong Y, Haque S, Chowdhury P, et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin Drug Metab Toxicol. 2019;15(5):417–427.
   PubMed Web of Science ®Google Scholar
• Bernal E, Marín I, Masiá M, et al. Statins in HIV-infected patients: potential beneficial effects and clinical use. AIDS Rev. 2017;19(2):59–71.
   PubMed Web of Science ®Google Scholar
• Chauvin B, Drouot S, Barrail-Tran A, et al. Drug–drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–831.
   PubMed Web of Science ®Google Scholar
• Oswald S, Meyer Zu Schwabedissen HE, Nassif A, et al. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):506–513.
   PubMed Web of Science ®Google Scholar
• Suchy D, Łabuzek K, Stadnicki A, et al. Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol Rep. 2011;63(6):1335–1348.
   PubMed Web of Science ®Google Scholar
• Gutierrez MDM, Mateo MG, Corbacho N, et al. Drug–drug interactions when treating HIV-related metabolic disorders. Expert Opin Drug Metab Toxicol. 2019;15(10):787–802.
   PubMed Web of Science ®Google Scholar
• Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017;17(1):551.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.
   PubMed Web of Science ®Google Scholar
• Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006;20(12):1675–1677.
   PubMed Web of Science ®Google Scholar
• Negredo E, Moltó J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006;20(17):2159–2164.
   PubMed Web of Science ®Google Scholar
• Boonthos K, Puttilerpong C, Pengsuparp T, et al. Short-term efficacy and safety of adding ezetimibe to current regimen of lipid-lowering drugs in human immunodeficiency virus-infected Thai patients treated with protease inhibitors. Jpn J Infect Dis. 2018;71(3):220–238.
   PubMed Web of Science ®Google Scholar
• Chow D, Chen H, Glesby MJ, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS. 2009;23(16):2133–2141.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Asghar AK, Holmes P, et al. Use of ezetimibe during HIV infection. J Antimicrob Chemother. 2009;63(1):218–220.
   PubMed Web of Science ®Google Scholar
• Leyes P, Martínez E, Larrousse M, et al. Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. BMC Infect Dis. 2014;14(1):497–496.
   PubMedGoogle Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135–113.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Study quality assessment tools: quality assessment tool for observational cohort and cross-sectional studies; 2021. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
   Google Scholar
• Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Waters D, Simpson RJ, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008;47(8):1105–1108.
   PubMed Web of Science ®Google Scholar
• Grandi AM, Nicolini E, Rizzi L, et al. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe + fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014;17:1–5.
   Web of Science ®Google Scholar
• Saeedi R, Johns K, Frohlich J, et al. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14(1):1–8.
   PubMedGoogle Scholar
• Chastain LM, Bain AM, Edwards KL, et al. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme a reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidol. 2007;1(6):634–639.
   PubMed Web of Science ®Google Scholar
• Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 2007;6(1):4–7.
   PubMedGoogle Scholar
• Van Den Berg-Wolf M, Klibanov OM, Gaughan JP, et al. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008;22(6):483–488.
   PubMed Web of Science ®Google Scholar
• Muñoz RP, Fernández SP, Conde AH, et al. Eficacia y seguridad de asociar ezetimiba a dosis bajas de atorvastatina en la hipercolesterolemia asociada al tratamiento antirretroviral en pacientes con el virus de la inmunodeficiencia humana. Clín Investig Arterioscler. 2009;21(4):185–189.
   Google Scholar
• Gili S, Grosso Marra W, D’Ascenzo F, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016;37(48):3600–3609.
   PubMed Web of Science ®Google Scholar
• Banach M, Dinca M, Ursoniu S, et al. A PRISMA-compliant systematic review and Meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res. 2016;111:343–356.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.
   PubMed Web of Science ®Google Scholar
• Kato ET, Cannon CP, Blazing MA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). J Am Heart Assoc. 2017;6(11):e006901.
   PubMed Web of Science ®Google Scholar